Factors determining long-term antitumor responses to immune checkpoint blockade therapy in melanoma Journal Article

   


Authors: Loo, K.; Smithy, J. W.; Postow, M. A.; Betof Warner, A.
Article Title: Factors determining long-term antitumor responses to immune checkpoint blockade therapy in melanoma
Abstract: With the increasing promise of long-term survival with immune checkpoint blockade (ICB) therapies, particularly for patients with advanced melanoma, clinicians and investigators are driven to identify prognostic and predictive factors that may help to identify individuals who are likely to experience durable benefit. Several ICB combinations are being actively developed to expand the armamentarium of treatments for patients who may not achieve long-term responses to ICB single therapies alone. Thus, negative predictive markers are also of great interest. This review seeks to deepen our understanding of the mechanisms underlying the durability of ICB treatments. We will discuss the currently available long-term data from the ICB clinical trials and real-world studies describing the survivorship of ICB-treated melanoma patients. Additionally, we explore the current treatment outcomes in patients rechallenged with ICB and the patterns of ICB resistance based on sites of disease, namely, liver or CNS metastases. Lastly, we discuss the landscape in melanoma in the context of prognostic or predictive factors as markers of long-term response to ICB. Copyright © 2022 Loo, Smithy, Postow and Betof Warner.
Keywords: signal transduction; survival; treatment response; overall survival; histopathology; review; nonhuman; follow up; cd8+ t lymphocyte; biomarkers; cell survival; ipilimumab; cancer immunotherapy; melanoma; progression free survival; quality of life; apoptosis; tumor volume; cell differentiation; antineoplastic activity; cytotoxicity; tumor regression; immune response; immunotherapy; cd4+ t lymphocyte; upregulation; immunosuppressive treatment; lymphocyte count; predictive value; rna sequence; tumor microenvironment; phase 2 clinical trial (topic); clinical outcome; eosinophil count; long-term response; immune checkpoint inhibitor; nivolumab; human; pembrolizumab; mass cytometry
Journal Title: Frontiers in Immunology
Volume: 12
ISSN: 1664-3224
Publisher: Frontiers Media S.A.  
Date Published: 2022-01-11
Start Page: 810388
Language: English
DOI: 10.3389/fimmu.2021.810388
PUBMED: 35087529
PROVIDER: scopus
PMCID: PMC8787112
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123446221&doi=10.3389%2ffimmu.2021.810388&partnerID=40&md5=b026d43a5e9650aca3b83f00bab7092d
Notes: Review -- Export Date: 1 March 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Michael Andrew Postow
    364 Postow
  2. Allison Betof Warner
    76 Betof Warner
  3. James William Smithy
    30 Smithy
  4. Kimberly Leticia Loo
    6 Loo
Related MSK Work